Study Comparing NX-5948 and Pirtobrutinib for Treating Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sponsor: Nurix Therapeutics, Inc.
ClinicalTrials ID:NCT07516093
This clinical trial is testing two different treatments, NX-5948 and Pirtobrutinib, to see which is more effective and safe for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or not responded to previous treatments.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this study is to compare the effectiveness and safety of two treatments, NX-5948 and Pirtobrutinib, in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to previous treatments. Participants in this study have already tried a type of treatment called covalent Bruton tyrosine kinase inhibitor (cBTKi) but need new options because their disease has progressed.
Eligibility Criteria
Inclusion Criteria
- Have a performance status score of 0 to 2, meaning fully active or restricted in physically strenuous activity but ambulatory.
- Have good organ and bone marrow function.
- Have a confirmed diagnosis of CLL or SLL that requires treatment according to specific medical guidelines.
- Have received at least one previous treatment for CLL or SLL that included a cBTKi and experienced disease progression during or after this treatment.
- For SLL patients, have measurable disease as shown by a CT scan.
Exclusion Criteria
- Have or are suspected to have prolymphocytic leukemia or Richter's transformation at any time before joining the study.
- Have taken an investigational drug or cancer treatment within a short period before starting the study treatment.
- Are currently taking systemic corticosteroids at a dose of 10 mg/day or more of prednisone or equivalent.
- Have previously been treated with a BTK degrader or a noncovalent BTKi.
- Have had a heart attack, unstable chest pain, or other significant heart issues within six months before starting the study treatment.
- Have had blood clots, a stroke, or bleeding in the brain within six months before starting the study treatment.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Central Georgia Cancer Care | 31210 | Macon | Georgia |
| Fort Wayne Medical Oncology and Hematology | 46804 | Fort Wayne | Indiana |
| Hematology Oncology of Indiana | 46260 | Indianapolis | Indiana |
| SCRI Oncology Partners | 37203 | Nashville | Tennessee |
| Texas Oncology - West Texas | 79124 | Midland | Texas |
| Virginia Cancer Specialists | 22201 | Fairfax | Virginia |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.